-+ 0.00%
-+ 0.00%
-+ 0.00%
Repligen to buy BioLife Solutions for USD 1.5 billion in cash-and-stock deal
Share
Listen to the news
Repligen to buy BioLife Solutions for USD 1.5 billion in cash-and-stock deal
  • Repligen agreed to acquire BioLife Solutions for an enterprise value of about USD 1.5 billion, paid 64% in stock, 36% in cash.
  • BioLife holders to receive USD 11.25 in cash plus 0.1442 Repligen shares per share, valued at USD 31.
  • Deal implies a 24% premium to BioLife’s 90-day VWAP through July 21, 2026; closing targeted for Q4 2026.
  • Repligen expects at least USD 20 million of year-one synergies, rising to at least USD 30 million in year two.
  • BioLife posted preliminary Q2 2026 revenue of USD 28.5 million, up 21% year over year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLife Solutions Inc. published the original content used to generate this news brief on July 22, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending